Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CTEC: Cholestech any other investors? -- Ignore unavailable to you. Want to Upgrade?

To: Boplicity who wrote (365)	12/16/1997 9:47:00 PM
From: Duane L. Olson	Read Replies (1) \| Respond to of 710

There are some folks who make great resources over on the Yahoo thread: messages.yahoo.com@m2.yahoo.com For example, here are some thoughts by MKC, who uses Cholestec's LDX product at work: " Part of the reason that I believe the LDX systems will gain ground in the pharmacy market is the undercurrent of pharmacists moving to get prescriptive authority. Some states are already looking into that ability. Of course, the pharmacist will work closely with a physician but will monitor medication dosages, etc. That's where the LDX will help in pharmacists. For example, a physician may order a cholesterol lowering med and the patient can monitor the dosage at his/her local pharmacy. If and when pharmacists gain prescriptive authority, they could actually change the dosage if the need arises. This, at least, is my understanding of the process. This comment gave added emphasis to my understanding of the contract to get LDX into the pharmacies.. I would encourage all the SI folks to stop over and visit the Yahoo thread.. dlo